Contrast Media pp 201-206 | Cite as

Acute Adverse Reactions to Gadolinium-Based Contrast Media

  • Henrik S. Thomsen
  • Georg M. Bongartz
Part of the Medical Radiology book series (MEDRAD)


Acute non-renal and renal adverse reactions occur after administration of gadolinium-based contrast media just as after iodine-based contrast media. However, the rate of acute non-renal adverse reactions is much lower after gadolinium-based contrast media than after iodine-based contrast media. Acute renal adverse reactions (contrast medium-induced nephropathy, CIN) do occur after gadolinium-based contrast media but are extremely infrequent after administration of the low doses (0.1–0.3 mmol l−1 kg−1) used for MRI. Knowledge about higher doses is limited, but the frequency of renal adverse reactions is predicted to be closer to that seen after iodine-based contrast media.


Nephrogenic Systemic Fibrosis Anaphylactoid Reaction Gadopentetate Dimeglumine Gadobenate Dimeglumine Gadoterate Meglumine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abujudeh HH, Kosaraju VK, Kaewlai R (2010) Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. Am J Roentgenol 194:430–434CrossRefGoogle Scholar
  2. Balzer JO, Loewe C, Davis K et al (2003) Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol 13:2067–2074PubMedCrossRefGoogle Scholar
  3. Bellin MF, Deray G, Assogba U et al (1992) Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10:115–118PubMedCrossRefGoogle Scholar
  4. Bleicher AG, Kanal E (2008) Assessment of adverse reactions to a newly approved MRI contrast agent: review of 23,533 administrations of gadobenate dimeglumine. Am J Roentgenol 191:W307CrossRefGoogle Scholar
  5. Briguori C, Colombo A, Airoldi F et al (2006) Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67:175–180PubMedCrossRefGoogle Scholar
  6. Brown JJ, Kristy RM, Stevens GR et al (2002) The OptiMARK clinical development program: summary of safety data. J Magn Reson Imaging 15:446–455PubMedCrossRefGoogle Scholar
  7. Davenport MS, Dillman JR, Cohan RH et al (2013) Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 266:773–782PubMedCrossRefGoogle Scholar
  8. De Ridder F, de Maeseneer M, Stadnik T et al (2001) Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30000 MR examinations. JBR-BTR 84:150–152PubMedGoogle Scholar
  9. Demaerel P, Marchal G, Wilms G et al (1994) Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5T. Neuroradiology 36:355–359PubMedCrossRefGoogle Scholar
  10. Dillman JR, Ellis JH, Cohan RH et al (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. Am J Roentgenol 189:1533–1538CrossRefGoogle Scholar
  11. Dillman JR, Ellis JH, Cohan RH et al (2008) Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. Am J Roentgenol 190:187–190CrossRefGoogle Scholar
  12. Elmstahl B, Nyman U, Leander P et al (2004) Gadolinium contrast media are more nephrotoxic than a low-osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. Acad Radiol 11:1219–1228PubMedCrossRefGoogle Scholar
  13. Elmstahl B, Leander P, Grant D et al (2007) Histomorphological changes after renal X-ray arteriography using iodine and gadolinium contrast media in an ischemic porcine model. Acta Radiol 23:1–11Google Scholar
  14. Ergun I, Keven K, Uruc I et al (2006) The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21:697–700PubMedCrossRefGoogle Scholar
  15. Greenen RWF, Krestin GP (2006) Non-tissue specific extracellular MR contrast media. In: Thomsen HS (ed) Contrast media: safety issues and ESUR guidelines. Springer, Heidelberg, pp 107–120CrossRefGoogle Scholar
  16. Haustein J, Laniado M, Niendorf HP et al (1993) Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186:855–860PubMedGoogle Scholar
  17. Haustein J, Niendorf HP, Krestin G et al (1992) Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 27(2):153–156Google Scholar
  18. Heborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58–62CrossRefGoogle Scholar
  19. Hunt CH, Hartman RP, Hesley CH (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: Retrospective review of 456,930 doses. Am J Roentgenol 193:1124–1127CrossRefGoogle Scholar
  20. Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs RD 10:133–145CrossRefGoogle Scholar
  21. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502PubMedCrossRefGoogle Scholar
  22. Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging. Safety update. Top Magn Reson Imaging 14:426–435PubMedCrossRefGoogle Scholar
  23. Li A, Wong CS, Wong MK et al (2006) Acute adverse reactions to magnetic resonance contrast media: gadolinium chelates. Br J Radiol 79:368–371PubMedCrossRefGoogle Scholar
  24. Morgan DE, Spann JS, Lockhart ME et al (2011) Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology 259:109–116PubMedCrossRefGoogle Scholar
  25. Murphy KJ, Brunberg JA, Cohen RH (1996) Adverse reactions to gadolinium contrast media: a review of 36 cases. Am J Roentgenol 167:847–849CrossRefGoogle Scholar
  26. Murphy KPJ, Szopinski KT, Cohan RH et al (1999) Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 6:656–664PubMedCrossRefGoogle Scholar
  27. Niendorf HP, Dinger JC, Haustein J et al (1991a) Tolerance data of Gd-DTPA: a review. Eur J Radiol 13:15–20PubMedCrossRefGoogle Scholar
  28. Niendorf HP, Haustein J, Cornelius I et al (1991b) Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22:222–228PubMedCrossRefGoogle Scholar
  29. Oudkerk M, Sijens PE, van Beek EJR et al (1995) Safety and efficacy of gadoterate meglumine (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75–78PubMedCrossRefGoogle Scholar
  30. Prince MR, Zhang H, Zou Z et al (2011) Incidence of immediate gadolinium contrast media reactions. Am J Roentgenol 196:138–143CrossRefGoogle Scholar
  31. Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12:205–213PubMedCrossRefGoogle Scholar
  32. Sam AD II, Morasch MD, Collins J et al (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313–318PubMedCrossRefGoogle Scholar
  33. Sharpe R, Levin D, Parker L, Rao V (2013) Previously sharp increases in growth of MR imaging have ceased and MR use is decreasing. American Roentgen Ray Washington DC, abstract # 037Google Scholar
  34. Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10:477–484PubMedCrossRefGoogle Scholar
  35. Swan SK, Baker JF, Free R et al (1999a) Pharmacokinetics, safety, and tolerability of gadoverset-amide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 9:317–321PubMedCrossRefGoogle Scholar
  36. Swan SK, Lambrecht LJ, Townsend R al (1999b) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34:443–448PubMedCrossRefGoogle Scholar
  37. Thomsen HS (1997) Frequency of acute adverse events to a nonionic lowosmolar contrast medium: the effect of verbal interview. Pharmacol Toxicol 80:108–110PubMedCrossRefGoogle Scholar
  38. Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses (case report). Eur Radiol 14:1654–1656PubMedGoogle Scholar
  39. Thomsen HS, Almen T, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605Google Scholar
  40. Thomsen HS, Webb JAW (2012) The Lalli and Weber effects and the incidence of acute non-renal adverse reactions to contrast media. Acta Radiol 53:953–954PubMedCrossRefGoogle Scholar
  41. Thomsen HS, Marckmann P, Logager VB (2007) Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 48:593–596PubMedCrossRefGoogle Scholar
  42. Thurnher SA, Capelastagui A, del Olmo FH et al (2001) Safety and effectiveness of single- versus triple-dose gadodiamide injection-enhanced MR angiography of the abdomen: a phase III double-blind multicenter study. Radiology 219:137–146PubMedCrossRefGoogle Scholar
  43. Tombach B, Bremer C, Reimer P et al (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651–657PubMedCrossRefGoogle Scholar
  44. Tresley RM, Stone LA, Fields N et al (1997) Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials. Neurology 48:832–835PubMedCrossRefGoogle Scholar
  45. Weber JCP (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD (eds) Side-effects of anti-inflammatory drugs, advances in inflammation research. Raven Press, New York, pp 1–7Google Scholar
  46. Yoshikawa K, Davies A (1997) Safety of ProHance in special populations. Eur Radiol 7(Suppl 5):S246–S250CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Diagnostic RadiologyCopenhagen University Hospital HerlevHerlevDenmark
  2. 2.Radiology and NuclearmedicineUniversity Hospital of BaselBaselSwitzerland

Personalised recommendations